Yuhan Corporation: Hyperlipidemias trials
The registry lists 13 Hyperlipidemias studies with Yuhan Corporation as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 1 10Phase 3 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236BNot yet recruitingNCT07730567Phase 1
- A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231CNot yet recruitingNCT07312773Phase 1
- A Study to Assess the Safety and Pharmacokinetics of AD-104-ACompletedNCT05703282Phase 1
- A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221BCompletedNCT05202405Phase 1
- Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072CompletedNCT03632668Phase 1
- Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012CompletedNCT03586037Phase 1
- Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and RosuvastatinCompletedNCT03116516Phase 1
- Clinical Trial to Evaluate the Efficacy and Safety of YHP1701CompletedNCT03103256Phase 3
- Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and HyperlipidemiaCompletedNCT03067688Phase 3
- A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and RosuvastatinCompletedNCT02951962Phase 1
- PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and RosuvastatinTerminatedNCT02608242Phase 1
- Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and HyperlipidemiaCompletedNCT01914432Phase 3
- Pharmacokinetic Drug Interaction Between Rosuvastatin and ValsartanCompletedNCT01609907Phase 1